Important note: Information in this article was accurate in May 2005. The state of the art may have changed since the publication date.
 |
AIDSWEEKLY Plus; Monday, May 2, 2005
Staff Medical Writers
According to recent research from Japan, "We established human peripheral blood mononuclear cell (PBMC)-transplanted R5 human immunodeficiency virus type 1 isolate JR-FL (HIV-1(JR-FL))-infected, nonobese diabetic-SCID, interleukin 2 receptor T-chain-knocked-out (NOG) mice, in which massive and systemic HIV-1 infection occurred."
"The susceptibility of the implanted PBMC to the infectivity and cytopathic effect of R5 HIV-1 appeared to stem from hyperactivation of the PBMC, which rapidly proliferated and expressed high levels of CCR5.
"When a novel spirodiketopiperazine-containing CCR5 inhibitor, AK602/ONO4128/GW873140 (molecular weight, 614), was administered to the NOG mice 1 day after R5 HIV-1 inoculation, the replication and cytopathic effects of R5 HIV-1 were significantly suppressed," wrote H. Nakata and colleagues at Kumamoto University.
"In saline-treated mice (n=7)," continued scientists, "the mean human CD4+/CD8+ cell ratio was 0.1 on day 16 after inoculation, while levels in mice (n=8) administered AK602 had a mean value of 0.92, comparable to levels in uninfected mice (n=7).
"The mean number of HIV-RNA copies in plasma in saline-treated mice were similar to106/ml on day 16, while levels in AK602-treated mice were 1.27x103/mL (P=0.001). AK602 also significantly suppressed the number of proviral DNA copies and serum p24 levels (P=0.001)."
"These data suggest that the present NOG mouse system should serve as a small-animal AIDS model and warrant that AK602 be further developed as a potential therapeutic for HIV-1 infection," the authors concluded.
Nakata and colleagues published their study in the Journal of Virology (Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. J Virol. 2005 Feb;79(4):2087-96.
For additional information, contact H. Mitsuya, Kumamoto University, Graduate School of Medicine, Department Infection Diseases, 1-1-1 Honjo, Kumamoto 8608556, Japan.
Publisher contact information for the Journal of Virology is: American Society Microbiology, 1752 N St. NW, Washington, DC 20036-2904, USA.
Keywords: Kumamoto, Japan, HIV/AIDS, CCR5 Antagonist, Pharmaceutical & Drug Development, NOG Murine Model, Genomics & Genetics.
This article was prepared by AIDS Weekly editors from staff and other reports.
Reference
Nakata H, Maeda K, Miyakawa T, et al., Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model, J Virol. 2005 Feb;79(4):2087-96.
PubMED Related articles Search
050502
AW050502
Copyright © 2005 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, Bridgestone/Firestone Charitable Trust, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2005. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright © 1980,2005. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.